Art

J-GLOBAL ID：202002216402718156   Reference number：20A2757068

Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation

プレおよびポストパゾパニブ時代における進行性軟部組織肉腫に対する第一選択治療の無作為化対照試験における全生存のための中間エンドポイントの代理性:メタ分析評価【JST・京大機械翻訳】

Author (5)： Tanaka Kazuhiro (Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Yufu City, Japan) ,  Kawano Masanori (Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Yufu City, Japan) ,  Iwasaki Tatsuya (Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Yufu City, Japan) ,  Itonaga Ichiro (Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Yufu City, Japan) ,  Tsumura Hiroshi (Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Yufu City, Japan)
Material： BMC Cancer (Web)
Volume： 19  Issue： 1  Page： 1-9  Publication year： 2019 
JST Material Number： U7305A  ISSN： 1471-2407  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： Overall survival is the true e...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A2757068&from=J-GLOBAL&jstjournalNo=U7305A") }}

Thesaurus term： correlation coefficient ,  English ,  drug therapy ,  effectiveness ,  robustness ,  meta-analysis ,  *randomized controlled trial ,  systematic review ,  *end point ,  molecular targeting drug ,  amino sugar ,  quinone ,  glycoside (except carbohydrate) ,  polyphenol ,  deoxysugar ,  pyranoside ,  phenol ether ,  polynuclear aromatic compound ,  hydroxy ketone ,  polyol
Semi thesaurus term： 悪性腫瘍 ,  *軟部組織肉腫 ,  無増悪生存期間 ,  ハザード比 , 【Automatic Indexing@JST】

Author keywords (6)： Advanced soft tissue sarcoma ,  Randomized controlled trial ,  First-line treatment ,  Doxorubicin ,  Endpoint ,  Surrogacy

JST classification (2)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Substance index (2)： Pazopanib ,  Doxorubicin

Reference (45)：

• Cancer facts and figures 2017; 2017; CR1; citation_publisher=American Cancer Society
• Soft tissue tumor registry in Japan 2015; 2015; CR2; citation_publisher=National Cancer Center
• Ann Oncol; Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up; ; 25; 2014; iii102-iii112; 10.1093/annonc/mdu254; citation_id=CR3
• Bramwell VH, Anderson D, Charette ML, Sarcoma disease site group. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev. 2003:CD003293.https://doi.org/10.1002/14651858.CD003293.
• J Clin Oncol; Progression-free survival is a surrogate for survival in advanced colorectal cancer; M Buyse, T Burzykowski, K Carroll, S Michiels, DJ Sargent, LL Miller; 25; 2007; 5218-5224; 10.1200/JCO.2007.11.8836; citation_id=CR5

Terms in the title (8)： パゾパニブ ,  軟部組織肉腫 ,  治療 ,  無作為化対照試験 ,  生存 ,  エンドポイント ,  メタ分析 ,  評価